5th Translational Research Conference
Acute Lymphoblastic Leukaemia
May 20-22, 2027 - Malahide (Dublin), Ireland
Chairpersons: Kathrin Bernt, Nicolas Boissel, Jan Cools, Ulla Wartiovaara-Kautto

Thursday, May 20th, 2027

08:30–08:40 Welcome by chairpersons

SESSION I – The biology of B-ALL
Chair(s): Mignon Loh (Seattle)

08:40-08:45.	Introduction	Mignon Loh (Seattle)
08:45-09:00	Genetic subtypes of B-ALL	Charles G. Mullighan (Memphis)
09:00-09:05	*Discussion*	
09:05-09:20	Lineage infidelity in ALL	Barbara Buldini (Padua)
09:20-09:25	*Discussion*	
09:25-09:40	How to integrate genetic classification into treatment stratification	Nicola Gökbuget (Frankfurt)
09:40-09:45	*Discussion*	
09:45-09:52	*Selected brief oral communication*	Speaker
09:52-09:55	Discussion	
09:55-10:25.	*Panel discussion*	

10:25-10:55 Coffee Break

SESSION II – The biology of T-ALL
Chair(s): Jan Cools (Leuven)

10:55-11:00	Introduction	Jan Cools (Leuven)
11:00-11:15	Genetic subtypes of T-ALL	Petri Pölönen (Memphis)
11:15-11:20	*Discussion*	
11:20-11:35	Metabolic changes in T-ALL	Guillaume Andrieu (Paris)
11:35-11:40	*Discussion*	
11:40-11:55	NKX2-1 expressing T-ALL	Kim De Keersmaecker (Leuven)
11:55-12:00	*Discussion*	

12:00-12:07	*Selected brief oral communication*	Speaker
12:07-12:10	*Discussion*	
12:10-12:40	*Panel discussion*	
12:40-14:30	***Lunch***	
13:20-14:20	**Possible slot for a satellite symposium**	

SESSION III – Immunotherapy I
Chair(s): Marc Mansour (London)

14:30-14:35	Introduction	Marc Mansour (London)
14:35-14:50	How to make a good bi/tri-specific antibody	Mignon Loh (Seattle)
14:50-14:55	*Discussion*	
14:55-15:10	New generation T-Cell engagers	Cristina Papayannidis (Bologna)
15:10-15:15	*Discussion*	
15:15-15:30	Deintensification	Sumit Gupta (Toronto)
15:30-15:35	*Discussion*	
15:35-15:42	*Selected brief oral communication*	Speaker
15:42-15:45	*Discussion*	
15:45-16:15	*Panel discussion*	
16:15-16:45	***Coffee break***	

SESSION IV – Immunotherapy II
Chair(s): Nicola Gökbuget (Frankfurt)

16:45-16:50	Introduction	Nicola Gökbuget (Frankfurt)
16:50-17:05	Lineage switch	Nirali Shah (Bethesda)
17:05 -17:10	*Discussion*	
17:10-17:25	Specific challenges of MRD monitoring after immunotherapy	Monika Brüggemann (Kiel)
17:25-17:30	*Discussion*	
17:30-17:45	Resistance mechanism to CD19 therapies	Kara Davis (Stanford)
17:45-17:50	*Discussion*	
17:50-17:57	*Selected brief oral communication*	Speaker
17:57-18:00	*Discussion*	
18:00-18:30	*Panel discussion*	
18:30-20:00	**Mentored Poster Walks and Welcome Get Together stand up buffet dinner**	

Friday, May 21st, 2027

08:00-09:00 3 Simultaneous Meet the Expert Sessions (Non Clinical)

1. Flow, qPCR or NGS: which MRD method for which clinical question? — Monika Brüggemann (Kiel)
2. Precision medicine in childhood ALL — Mignon Loh (Seattle)
3. Therapeutic drug monitoring in ALL: from concept to daily practice — Kjeld Schmiegelow (Copenhagen)

09:00-10:00 **Possible slot for a satellite symposium**

10:00-10:30 ***Coffee break***

SESSION V – Extramedullary disease
Chair(s): Sabina Chiaretti (Rome)

10:30-10:35	Introduction	Sabina Chiaretti (Rome)
10:35-10:50	Biological differences of ALL cells homing to CNS	Michael Rieger (Frankfurt)
10:50-10:55	*Discussion*	
10:55-11:10	Increased intrinsic quiescence and extrinsic immunosuppressice environment in the CNS	Katrin Ottersbach (Edinburgh)
11:10-11:15	*Discussion*	
11:15-11:30	CNS involvement: unmet needs and therapeutic approaches	Kjeld Schmiegelow (Copenhagen)
11:30-11:35	*Discussion*	
11:35-11:42	*Selected brief oral communication*	Speaker
11:42-11:45	*Discussion*	
11:45-12:15	*Panel discussion*	

12:15-13:55 ***Lunch***

SESSION VI – Host factors
Chair(s): Ulla Wartiovaara-Kautto (Helsinki)

13:55-14:00	Introduction	Ulla Wartiovaara-Kautto (Helsinki)
14:00-14:15	Germline	Marion K. Mateos (Sydney)
14:15-14:20	*Discussion*	
14:20-14:35	Impact of non european ancestries on risk stratification and response	Haley M. Newman (Philadelphia)
14:35-14:40	*Discussion*	
14:40-14:55	Microbiome	Davide Leardini (Bologna)
14:55-15:00	*Discussion*	

15:00-15:07	*Selected brief oral communication*	Speaker
15:07-15:10	*Discussion*	
15:10-15:40	*Panel discussion*	
15:40-16:10	***Coffee break***	

SESSION VII – Drug targets and pharmacogenomics
Chair(s): Kim de Keersmaecker (Leuven)

16:10-16:15	Introduction	Kim de Keersmaecker (Leuven)
16:15-16:30	Pharmacogenomics	Mary V. Relling (Memphis)
16:30-16:35	*Discussion*	
16:35-16:50	Drug screening in ALL	Jean-Pierre Bourquin (Zurich)
16:50-16:55	*Discussion*	
16:55-17:10	GSK3β inhibitors in acute lymphoblastic leukaemia	Markus Müschen (New Haven)
17:10-17:15	*Discussion*	
17:15-17:22	*Selected brief oral communication*	Speaker
17:22-17:25	*Discussion*	
17:25-17:55	*Panel discussion*	
18:05-19:05	**Possible slot for a satellite symposium**	

Saturday, May 22nd, 2027

07:40-08:40 **3 Simultaneous Meet the Expert Sessions (Clinical)**

1. How far can we safely de-escalate chemotherapy in frontline B-ALL? — Sumit Gupta (Toronto)
2. Allo-HSCT after CAR-T cell therapy: when and for whom? — Ibrahim Aldoss (Duarte)
3. Treatment and monitoring of front-line Ph+ B-ALL — Sabina Chiaretti (Rome)

SESSION VIII – TKi / Menin - Targeted therapies
Chair(s): Charles Mullighan (Memphis)

08:45-08:50	Introduction	Charles Mullighan (Memphis)
08:50-09:05	Rationale for targeted therapy in T-ALL	Mathieu Simonin (Paris)
09:05-09:10	*Discussion*	
09:10-09:25	Menin inhibitors in ALL	Florian Perner (Hannover)
09:25-09:30	*Discussion*	
09:30-09:45	Combining immunotherapy and TKI	Sabina Chiaretti (Rome)
09:45-09:50	*Discussion*	

09:50-09:57	*Selected brief oral communication*	Speaker
09:57-10:00	*Discussion*	
10:00-10:30	*Panel discussion*	
10:30-11:00	***Coffee break***	

SESSION IX – CAR-T
Chair(s): Nicolas Boissel (Paris)

11:00-11:05	Introduction	Nicolas Boissel (Paris)
11:05-11:20	CAR-T for T-ALL	Marc Mansour (London)
11:20-11:25	*Discussion*	
11:25-11:40	Next generation CAR-T for leukaemia	Marco Ruella (Philadelphia)
11:40-11:45	*Discussion*	
11:45-12:00	Challenges for frontline CAR-T development	Ibrahim Aldoss (Duarte)
12:00-12:05	*Discussion*	
12:05-12:12	*Selected brief oral communication*	Speaker
12:12-12:15	*Discussion*	
12:15-12:45	*Panel discussion*	
12:45-12:50	***Closing Remarks***	

MEETING CLOSURE

**Pending confirmation*